Innovative Risk Assessment Tool Promises Enhanced Detection of Ovarian Cancer

Researchers at Queen Mary University of London have introduced and validated a novel diagnostic aid aimed at enabling general practitioners (GPs) to identify ovarian cancer earlier. This new tool integrates results from a standard blood test measuring Cancer Antigen 125 (CA125) levels with a woman’s age, creating a personalized risk score that enhances diagnostic accuracy. Two extensive studies involving over 340,000 women across England have demonstrated the effectiveness of this approach, particularly for women over the age of 50, making it a cost-effective option for the NHS.

The first study showed that this risk assessment model, named Ovatools, could significantly improve the detection of ovarian cancer by identifying women at higher risk who require urgent referral and further investigation. The second study confirmed that implementing Ovatools for women over 50 would be financially viable, leading to earlier diagnosis and treatment while remaining within NHS affordability parameters. Both studies are published in the British Journal of Cancer.

Ovarian cancer remains the sixth leading cause of cancer deaths among women in the UK, with many cases diagnosed late when survival chances are limited. Current diagnostic practices rely on symptom-based blood tests and ultrasound referrals, but such methods do not account for variations in risk related to age and blood marker levels. By combining a woman’s age with CA125 test results, Ovatools provides a more reliable risk estimate, potentially leading to better patient outcomes.

Dr. Garth Funston, a Clinical Senior Lecturer involved in the research, highlighted the utility of this tool, noting that it can assist GPs in decision-making by better stratifying patients based on their risk. Experts from cancer research and healthcare emphasized that such innovations are vital in improving early detection rates and reducing late-stage diagnoses, which are associated with poor survival rates.

With approximately 7,500 women in the UK diagnosed annually, and many diagnosed at advanced stages, advancements like Ovatools could turn the tide towards earlier detection. Awareness remains crucial, as symptoms such as persistent bloating, abdominal pain, and changes in bowel or bladder habits warrant prompt medical consultation. Overall, this personalized risk score marks a promising step forward in ovarian cancer screening and management.